#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Usher's syndrome Follicular lymphoma stage I Cold type haemolytic anaemia Biliary neoplasm Acute lymphocytic leukaemia Prophylaxis against transplant rejection Familial haemophagocytic lymphohistiocytosis Alveolar proteinosis Transplant rejection Familial hypertriglyceridaemia Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Herpes simplex Glycogen storage disease type V Burkitt's lymphoma refractory Haemophilia More trials…

    Learn about Rare Diseases

    Von Willebrand’s disease – Treatment Mantle cell lymphoma stage III – Trials in Disease Pemphigoid – Treatment Carcinoid syndrome – Trials in Disease Familial haemophagocytic lymphohistiocytosis – Diagnostics Chordoma – Basic Information Amyotrophic lateral sclerosis – Basic Information Familial amyotrophic lateral sclerosis – Life with Disease Medulloblastoma recurrent – Diagnostics Systemic sclerosis pulmonary More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pentixafor Gallium Ga-68 Ecopipam Hydrochloride Sodium Alginate Fosfomycin Simvastatin Elamipretide Trihydrochloride Fenofibrate Micronised Cx-037231 Human Immunoglobulin G Cefotaxime GSKVX000000046019 Ligelizumab Tumor Necrosis Factor-Alpha Desogestrel Tulisokibart Thalidomide Degarelix Nmd670 ALN-4324 Telitacicept More therapies…

    Learn about Your Condition

    Vasoplegia syndrome Pancreatitis relapsing Cataract Metastatic gastric cancer Alcoholic liver disease Cervix carcinoma stage II Hypercholesterolaemia Vulvovaginal pruritus Injury Retroperitoneal cancer Psoriatic arthropathy Pouchitis Synovial sarcoma metastatic Spinal cord injury Respiratory distress More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Szpital Wojewodzki W Opolu Sp. z o.o.

Szpital Wojewodzki W Opolu Sp. z o.o.

Ul. Katowicka 64, Opole, 45-061, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Ziftomenib
    • Azacitidine
    • Cytarabine
    Belgium Czechia France Germany Greece Hungary +4

  • Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Revumenib
    • Cytarabine
    • Daunorubicin Hydrochloride
    Austria Belgium Czechia France Germany Greece +7

  • A Study Comparing DZD8586 to Other Treatments for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Idelalisib
    • [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL
    • Bendamustine Hydrochloride
    Italy Poland

  • Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia refractory
    • Diffuse large B-cell lymphoma recurrent
    Investigated Drugs:
    • BGB-16673
    • Zanubrutinib
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    Germany Italy Poland

  • Study on the Safety and Effectiveness of HDP-101 for Patients with Relapsed or Refractory Multiple Myeloma

    Recruiting

    2 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Hdp-101
    Germany Hungary Poland Romania Spain

  • Study of SP-420 for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

    Recruiting

    2 1 1
    Investigated Drugs:
    • (S)-4,5-Dihydro-2-[2-Hydroxy-4-(3,6-Dioxaheptyloxy)Phenyl]-4-Methyl-4-Thiazolecarboxylic Acid
    Denmark Greece Italy Poland

  • Study of TL-895 and Navtemadlin for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • 1-4-{[6-Amino-5-(4-Phenoxy-Phenyl)-Pyrimidin-4-Ylamino]-Methyl}-4-Fluoro-Piperidin-1-Yl)-Propenone
    Hungary Poland

  • Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Myelofibrosis
    • Primary myelofibrosis
    Investigated Drugs:
    • Navtemadlin
    • Danazol
    • Hydroxycarbamide
    Bulgaria Croatia Czechia France Germany Greece +7

  • Study of Mosunetuzumab and Polatuzumab Vedotin for Patients with Diffuse Large B-Cell Lymphoma After Initial Treatment or in Elderly/Unfit Untreated Patients

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Polatuzumab Vedotin
    • Mosunetuzumab
    • Tocilizumab
    Poland Spain

  • Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    • Epcoritamab
    Austria Belgium Bulgaria Croatia Czechia Denmark +10
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!